| 4.57 0.21 (4.82%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.75 | 1-year : | 6.45 |
| Resists | First : | 4.92 | Second : | 5.53 |
| Pivot price | 4.43  |
|||
| Supports | First : | 3.95 | Second : | 3.28 |
| MAs | MA(5) : | 4.44 |
MA(20) : | 4.57 |
| MA(100) : | 4.62 |
MA(250) : | 6.41 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 52 |
D(3) : | 44.8 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 21.39 | Low : | 3.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NEUP ] has closed below upper band by 22.2%. Bollinger Bands are 37.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.64 - 4.67 | 4.67 - 4.69 |
| Low: | 4.18 - 4.2 | 4.2 - 4.22 |
| Close: | 4.53 - 4.57 | 4.57 - 4.61 |
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
Fri, 26 Jun 2026
Neuphoria Therapeutics (NEUP) Confirms Acquisition Talks with Sc - GuruFocus
Fri, 26 Jun 2026
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc - GlobeNewswire
Fri, 26 Jun 2026
Neuphoria Therapeutics Inc. Actuals & Estimates (NASDAQ:NEUP) - TradingView
Fri, 26 Jun 2026
NEUP Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 24 Jun 2026
Neuphoria Therapeutics Inc (NEUP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Wed, 17 Jun 2026
Neuphoria Therapeutics Inc (NEUP) Institutional Confidence - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.19e+006 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 46 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.4e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 110 % |
| Return on Assets (ttm) | 513.3 % |
| Return on Equity (ttm) | -28 % |
| Qtrly Rev. Growth | -13270 % |
| Gross Profit (p.s.) | 2.78 |
| Sales Per Share | 2.78 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | -8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 1.64 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 36840 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|